Levothyroxine Supplementation for Heart Transplant Recipients
Recruiting · NCT06428097 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, San Francisco
View the official record on ClinicalTrials.gov →Interventions studied
LevothyroxineNormal saline
What this trial is about
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants must be listed for heart transplantation
- Age ≥18 years
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
- Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy
- Patients with a known allergy or intolerance to levothyroxine
- Patients participating in another study evaluating an investigational drug within the past 30 days.
Where it is running
1 location listed across 1 US state.
- University of California, San Francisco - San Francisco, California, United States